This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2007 Mar 15;13(6):1625-9.

doi: 10.1158/1078-0432.CCR-06-2966.

Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells

Wanping Xu¹, Len Neckers

Affiliations

PMID: 17363512
DOI: 10.1158/1078-0432.CCR-06-2966

Review

Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells

Wanping Xu et al. Clin Cancer Res. 2007.

. 2007 Mar 15;13(6):1625-9.

doi: 10.1158/1078-0432.CCR-06-2966.

Authors

Wanping Xu¹, Len Neckers

Affiliation

¹ Urologic Oncology Branch, National Cancer Institute, Bethesda, MD 20892-1107, USA.

PMID: 17363512
DOI: 10.1158/1078-0432.CCR-06-2966

No abstract available

PubMed Disclaimer

Comment on

Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.
Ramanathan RK, Egorin MJ, Eiseman JL, Ramalingam S, Friedland D, Agarwala SS, Ivy SP, Potter DM, Chatta G, Zuhowski EG, Stoller RG, Naret C, Guo J, Belani CP. Ramanathan RK, et al. Clin Cancer Res. 2007 Mar 15;13(6):1769-74. doi: 10.1158/1078-0432.CCR-06-2233. Clin Cancer Res. 2007. PMID: 17363531 Clinical Trial.
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF, Kelly WK, DeLaCruz A, Curley T, Heller G, Larson S, Schwartz L, Egorin MJ, Rosen N, Scher HI. Solit DB, et al. Clin Cancer Res. 2007 Mar 15;13(6):1775-82. doi: 10.1158/1078-0432.CCR-06-1863. Clin Cancer Res. 2007. PMID: 17363532 Free PMC article. Clinical Trial.
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study.
Bagatell R, Gore L, Egorin MJ, Ho R, Heller G, Boucher N, Zuhowski EG, Whitlock JA, Hunger SP, Narendran A, Katzenstein HM, Arceci RJ, Boklan J, Herzog CE, Whitesell L, Ivy SP, Trippett TM. Bagatell R, et al. Clin Cancer Res. 2007 Mar 15;13(6):1783-8. doi: 10.1158/1078-0432.CCR-06-1892. Clin Cancer Res. 2007. PMID: 17363533 Clinical Trial.
A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study.
Weigel BJ, Blaney SM, Reid JM, Safgren SL, Bagatell R, Kersey J, Neglia JP, Ivy SP, Ingle AM, Whitesell L, Gilbertson RJ, Krailo M, Ames M, Adamson PC. Weigel BJ, et al. Clin Cancer Res. 2007 Mar 15;13(6):1789-93. doi: 10.1158/1078-0432.CCR-06-2270. Clin Cancer Res. 2007. PMID: 17363534 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Silverchair Information Systems
Other Literature Sources
- The Lens - Patent Citations Database